Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab

Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab

Abstract Background Overweight and obese patients with solid tumors receiving anti-programmed cell death-1 (PD-1)/PD-ligand-1(PD-L1) immune checkpoint inhibitors exhibit improved survival and higher risk of immune-related adverse events (irAEs) than those with a normal body mass index (BMI). In clas...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rosaria De Filippi, Fortunato Morabito, Armando Santoro, Giovanni Tripepi, Francesco D’Alò, Luigi Rigacci, Francesca Ricci, Emanuela Morelli, Pier Luigi Zinzani, Antonio Pinto
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
Hodgkin lymphoma
Immune checkpoint inhibitors
Body mass index
Immune-related adverse events
Medicine
R
Acceso en línea:https://doaj.org/article/f8e8de9a4961465ba54ef26969155fce
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/f8e8de9a4961465ba54ef26969155fce

Ejemplares similares